What is the Return on Assets (ROA) of Merus this year?
The Return on Assets (ROA) of Merus is -0.34 undefined this year.
Merus ROA 2024
Merus ROA
-0.34
Ticker
MRUS
ISIN
NL0011606264
WKN
A2AKFX
In 2024, Merus's return on assets (ROA) was -0.34, a -2.38% increase from the -0.35 ROA in the previous year.
Merus Aktienanalyse
What does Merus do?
Merus NV is a Dutch biotechnology company specialized in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2003 by Ton Logtenberg and Piet Gros and is headquartered in Utrecht. Merus' business model is based on the development of bispecific antibodies, which can bind to two different target structures simultaneously. These antibodies can specifically attack and destroy tumor cells by minimizing their binding to healthy cells, providing Merus with a high potential for cancer therapy and other diseases. The company is divided into two main divisions: Merus BV and Merus US Inc. Merus BV specializes in the development of bispecific antibodies and operates its own manufacturing facility in Utrecht, while Merus US Inc. focuses on the clinical development of cancer immunotherapies. Merus offers a variety of products, including Bispecific Antibodies for Multiple Targets (BAMTs), Multi-specific Antibodies (MSAs), TrioBody platform, and Smart-chemotherapy platform. The BAMT program aims to develop bispecific antibodies that can bind to multiple target structures simultaneously, enhancing their effectiveness against tumor cells. The company's MSA products aim to introduce a bispecific antibody system with specialized drainage function to enhance the efficiency of cancer treatments. Merus' TrioBody platform represents a form of bispecific antibodies specifically tailored to cells in tumors, providing a higher efficacy in destroying tumor cells compared to conventional antibodies. Merus' Smart-Chemotherapy platform aims to increase the efficiency of chemotherapy drugs by delivering the medication specifically to tumor cells, maximizing its effect on tumor cells while minimizing its effect on normal cells. The company has entered into various partnerships and collaborations with other companies to advance its research and development in the field of cancer immunotherapy. In 2018, Merus signed an agreement with Incyte, granting Incyte the right to use Merus' bispecific antibody platform for cancer treatment. Additionally, Merus has formed strategic alliances with other biotechnology companies such as Jazz Pharmaceuticals and Loxo Oncology to further develop in various areas of cancer immunotherapy. Merus is committed to continue investing in research and development of its antibody technology to increase the effectiveness of cancer treatments and provide patients worldwide with new therapies to combat cancer. Merus ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Merus's Return on Assets (ROA)
Merus's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Merus's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Merus's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Merus’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Merus stock
What was the ROA of Merus compared to the previous year?
The ROA of Merus has increased by -2.38% compared to the previous year.
What consequences do high ROA have for investors of Merus?
A high ROA is advantageous for investors of Merus, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Merus?
A low ROA can be unfavorable for investors of Merus as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Merus affect the company?
An increase in ROA of Merus can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Merus impact the company?
A reduction in the ROA of Merus can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Merus?
Some factors that can influence the ROA of Merus include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Merus important for investors?
The ROA of Merus is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Merus take to improve ROA?
To improve ROA, Merus can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Merus pay?
Over the past 12 months, Merus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Merus is expected to pay a dividend of 0 USD.
What is the dividend yield of Merus?
The current dividend yield of Merus is .
When does Merus pay dividends?
Merus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Merus?
Merus paid dividends every year for the past 0 years.
What is the dividend of Merus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Merus located?
Merus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Merus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Merus from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
When did Merus pay the last dividend?
The last dividend was paid out on 9/13/2024.
What was the dividend of Merus in the year 2023?
In the year 2023, Merus distributed 0 USD as dividends.
In which currency does Merus pay out the dividend?
The dividends of Merus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Merus
Our stock analysis for Merus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
